The Hyderabad-based Suven Life Sciences Ltd has received product patent, EP 1581492 for its clinical candidate SUVN-502 from the European Patent Office (EPO), which is valid until June 2023.
Commenting on the development Venkat Jasti, CEO of Suven Life Sciences, said, "We are very pleased by the grant of this patent for our clinical candidate SUVN-502 which is being developed for CNS disorders in the treatment of cognitive impairment associated with neuro-degenerative disorders like Alzheimer's disease (AD), Attention Deficit Hyperactivity Disorder (ADHD), memory impairment associated with aging and schizophrenia etc, the unmet medical needs".
He added that the potential market opportunity for these indications is more than $18 billion globally. Granting of this patent to our clinical candidate SUVN-502 is more timely and relevant now that the candidate is entering into clinical trials. Securing patent protection for our discoveries enhanced the value of our technologies and products substantially.
With the latest one, Suven has four European product patents and all of them have been validated in all the 37 member countries of Europe including major markets like Germany, Switzerland, Denmark, Spain, France, United Kingdom, Italy, Netherlands, Poland, Sweden and Finland. The company stated that EP 1581492 is an exclusive intellectual property (IP) of Suven and was achieved through the internal discovery research efforts.
In addition to this Suven has obtained product patents from USA (4), India (4), Australia (2), Eurasia (2), Korea (2), Mexico (2), New Zeeland (2), and Singapore (2). The granted claims of all these patents include the class of selective 5-HT compounds discovered by Suven and are being developed for the treatment of debilitating central nervous system (CNS) disorders such as Alzheimer's disease, ADHD, depression, Huntington's disease, MCI, memory impairments associated with aging, Parkinson's disease, Schizophrenia, vascular dementia and obesity.